GRTS vs. ATRA, CLLS, AGEN, BLUE, DSGN, ATAI, ZVRA, CRMD, ACRV, and IMMP
Should you be buying Gritstone bio stock or one of its competitors? The main competitors of Gritstone bio include Atara Biotherapeutics (ATRA), Cellectis (CLLS), Agenus (AGEN), bluebird bio (BLUE), Design Therapeutics (DSGN), Atai Life Sciences (ATAI), Zevra Therapeutics (ZVRA), CorMedix (CRMD), Acrivon Therapeutics (ACRV), and Immutep (IMMP). These companies are all part of the "medical" sector.
Atara Biotherapeutics (NASDAQ:ATRA) and Gritstone bio (NASDAQ:GRTS) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their analyst recommendations, valuation, community ranking, media sentiment, profitability, risk, dividends, earnings and institutional ownership.
Atara Biotherapeutics has a beta of 0.52, suggesting that its stock price is 48% less volatile than the S&P 500. Comparatively, Gritstone bio has a beta of 0.5, suggesting that its stock price is 50% less volatile than the S&P 500.
Atara Biotherapeutics currently has a consensus price target of $355.50, suggesting a potential upside of 3,395.58%. Gritstone bio has a consensus price target of $4.75, suggesting a potential upside of 627.97%. Given Gritstone bio's higher probable upside, analysts plainly believe Atara Biotherapeutics is more favorable than Gritstone bio.
70.9% of Atara Biotherapeutics shares are held by institutional investors. Comparatively, 48.5% of Gritstone bio shares are held by institutional investors. 3.7% of Atara Biotherapeutics shares are held by company insiders. Comparatively, 4.6% of Gritstone bio shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
In the previous week, Gritstone bio had 17 more articles in the media than Atara Biotherapeutics. MarketBeat recorded 19 mentions for Gritstone bio and 2 mentions for Atara Biotherapeutics. Gritstone bio's average media sentiment score of 0.76 beat Atara Biotherapeutics' score of 0.05 indicating that Atara Biotherapeutics is being referred to more favorably in the media.
Atara Biotherapeutics has a net margin of -671.70% compared to Atara Biotherapeutics' net margin of -926.13%. Gritstone bio's return on equity of 0.00% beat Atara Biotherapeutics' return on equity.
Atara Biotherapeutics received 287 more outperform votes than Gritstone bio when rated by MarketBeat users. However, 69.61% of users gave Gritstone bio an outperform vote while only 67.35% of users gave Atara Biotherapeutics an outperform vote.
Gritstone bio has higher revenue and earnings than Atara Biotherapeutics. Gritstone bio is trading at a lower price-to-earnings ratio than Atara Biotherapeutics, indicating that it is currently the more affordable of the two stocks.
Summary
Atara Biotherapeutics and Gritstone bio tied by winning 9 of the 18 factors compared between the two stocks.
Get Gritstone bio News Delivered to You Automatically
Sign up to receive the latest news and ratings for GRTS and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding GRTS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Gritstone bio Competitors List
Related Companies and Tools
